ITOS VS ERAS Stock Comparison
Performance
ITOS10/100
10/100
ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.
ERAS10/100
10/100
ERAS returned -71.18% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Sentiment
ITOS72/100
72/100
ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.
ERAS
"Sentiment" not found for ERAS
Technicals
ITOS14/100
14/100
ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.
ERAS64/100
64/100
ERAS receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
ITOS10/100
10/100
ITOS has missed earnings 5 times in the last 20 quarters.
ERAS100/100
100/100
ERAS has missed earnings 1 times in the last 20 quarters.
Profit
ITOS31/100
31/100
Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.
ERAS10/100
10/100
Out of the last 15 quarters, ERAS has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
ITOS40/100
40/100
ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
ERAS46/100
46/100
ERAS has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
All score calculations are broken down here to help you make more informed investing decisions
iTeos Therapeutics, Inc. Common Stock Summary
Nasdaq / ITOS
Healthcare
Biotechnology
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Erasca, Inc. Common Stock Summary
Nasdaq / ERAS
Healthcare
Biotechnology
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ITOS to other companies in the same or a similar industry.